Paul Stoffels

Global health care giant Johnson & Johnson (NYSE: JNJ) is proceeding with a Phase 3 trial of its coronavirus vaccine, and it believes a single dose will offer protection against the virus "very quickly," J&J Chief Scientific Officer Dr. Paul Stoffels said on CNBC's "...

Johnson & Johnson (NYSE: JNJ) could play a role in fighting the coronavirus, but a vaccine could take up to a year to develop. What Happened Johnson & Johnson tasked dozens of scientists across the world to work on a vaccine for the fast-spreading coronavirus and the company is "pretty...

This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...